Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue S, 2015, Pages S50-S55

  Sallman, David A ^a   Padron, Eric ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

ASXL1; Chronic myelomonocytic leukemia; Hypomethylating agent; Next generation sequencing; TET2

Indexed keywords

AZACITIDINE; BIOLOGICAL MARKER; CYTARABINE; DECITABINE; ETOPOSIDE; HYDROXYUREA;

ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; GENE MUTATION; HUMAN; NEXT GENERATION SEQUENCING; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; GENETICS; PROGNOSIS;

HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; PROGNOSIS;

EID: 84939631861     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.03.005     Document Type: Review

References (44)

1. M. Margulies, M. Egholm, W.E. Altman, and et al. Genome sequencing in microfabricated high-density picolitre reactors Nature 437 2005 376 380
2. K. Yoshida, M. Sanada, Y. Shiraishi, and et al. Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 2011 64 69
3. M. Meggendorfer, A. Roller, T. Haferlach, and et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML) Blood 120 2012 3080 3088
4. U. Germing, N. Gattermann, H. Minning, A. Heyll, and C. Aul Problems in the classification of CMML-dysplastic versus proliferative type Leuk Res 22 1998 871 878
5. J.W. Vardiman, J. Thiele, D.A. Arber, and et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
6. L. Malcovati, E. Hellstrom-Lindberg, D. Bowen, and et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Blood 122 2013 2943 2964
7. E. Such, J. Cervera, D. Costa, and et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia Haematologica 96 2011 375 383
8. A. Kohlmann, V. Grossmann, H.U. Klein, and et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1 J Clin Oncol 28 2010 3858 3865
9. E. Papaemmanuil, M. Gerstung, L. Malcovati, and et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes Blood 122 2013 3616 3627 quiz 99
10. R. Itzykson, O. Kosmider, A. Renneville, and et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia J Clin Oncol 31 2013 2428 2436
11. A.M. Jankowska, H. Makishima, R.V. Tiu, and et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A Blood 118 2011 3932 3941
12. R.L. Levine, M. Loriaux, B.J. Huntly, and et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia Blood 106 2005 3377 3379
13. J.W. Tyner, H. Erickson, M.W. Deininger, and et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients Blood 113 2009 1749 1755
14. V. Gelsi-Boyer, V. Trouplin, J. Adelaide, and et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia Br J Haematol 145 2009 788 800
15. A.J. Dunbar, L.P. Gondek, C.L. O'Keefe, and et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies Cancer Res 68 2008 10349 10357
16. M.C. Kuo, D.C. Liang, C.F. Huang, and et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation Leukemia 23 2009 1426 1431
17. L. Malcovati, E. Papaemmanuil, I. Ambaglio, and et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia Blood 124 2014 1513 1521
18. R. Itzykson, O. Kosmider, A. Renneville, and et al. Clonal architecture of chronic myelomonocytic leukemias Blood 121 2013 2186 2198
19. E. Padron, S. Yoder, S. Kunigal, and et al. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia Blood 123 2014 3675 3677
20. F. Onida, H.M. Kantarjian, T.L. Smith, and et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients Blood 99 2002 840 849
21. E. Padron, R. Komrokji, and A.F. List The clinical management of chronic myelomonocytic leukemia Clin Adv Hematol Oncol 12 2014 172 178
22. K. Takahashi, N. Pemmaraju, P. Strati, and et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia Blood 122 2013 2807 2811 quiz 920
23. P. Greenberg, C. Cox, M.M. LeBeau, and et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
24. U. Germing, A. Kundgen, and N. Gattermann Risk assessment in chronic myelomonocytic leukemia (CMML) Leuk Lymphoma 45 2004 1311 1318
25. A. Worsley, D.G. Oscier, J. Stevens, and et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival Br J Haematol 68 1988 17 21
26. I. Gonzalez-Medina, J. Bueno, A. Torrequebrada, A. Lopez, T. Vallespi, and I. Massague Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center Leuk Res 26 2002 821 824
27. U. Germing, C. Strupp, M. Aivado, and N. Gattermann New prognostic parameters for chronic myelomonocytic leukemia Blood 100 2002 731 732 author reply 2-3
28. E. Padron, N.H. Ali, D. Peker, and et al. A comparison of prognostic models for chronic myelomonocytic leukemia (CMML) in the era of hypomethylating agents Blood 120 2012 1695
29. E. Such, U. Germing, L. Malcovati, and et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia Blood 121 2013 3005 3015
30. O. Kosmider, V. Gelsi-Boyer, M. Cheok, and et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood 114 2009 3285 3291
31. O. Kosmider, V. Gelsi-Boyer, M. Ciudad, and et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia Haematologica 94 2009 1676 1681
32. V. Gelsi-Boyer, V. Trouplin, J. Roquain, and et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia Br J Haematol 151 2010 365 375
33. M.M. Patnaik, E. Padron, R.R. LaBorde, and et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes Leukemia 27 2013 1504 1510
34. R. Bejar, K. Stevenson, O. Abdel-Wahab, and et al. Clinical effect of point mutations in myelodysplastic syndromes N Engl J Med 364 2011 2496 2506
35. E. Padron, G. Garcia-Manero, M.M. Patnaik, and et al. An international data set for the study of chronic myelomonocytic leukemia (CMML) validates modern prognostic scoring systems and demonstrates a critical need for novel prognostication strategies Blood 120 2014 530
36. P. Fenaux, G.J. Mufti, E. Hellstrom-Lindberg, and et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
37. E. Wattel, A. Guerci, B. Hecquet, and et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group Blood 88 1996 2480 2487
38. L. Ades, M.A. Sekeres, A. Wolfromm, and et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine Leuk Res 37 2013 609 613
39. T. Braun, R. Itzykson, A. Renneville, and et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial Blood 118 2011 3824 3831
40. P.W. Wijermans, B. Ruter, M.R. Baer, J.L. Slack, H.I. Saba, and M. Lubbert Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML) Leuk Res 32 2008 587 591
41. L. Fianchi, M. Criscuolo, M. Breccia, and et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study Leuk Lymphoma 54 2013 658 661
42. C. Bally, L. Ades, A. Renneville, and et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine Leuk Res 38 2014 751 755
43. R. Bejar, A. Lord, K. Stevenson, and et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients Blood 124 2014 2705 2712
44. R. Bejar, K.E. Stevenson, B. Caughey, and et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation J Clin Oncol 32 2014 2691 2698